{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:04:19Z","timestamp":1780585459740,"version":"3.54.1"},"reference-count":97,"publisher":"The Endocrine Society","issue":"Supplement_1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Crinetics Pharmaceuticals, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Excess growth hormone (GH) production leading to acromegaly most commonly emanates from an adenomatous pituitary somatotroph. Understanding the pathogenesis of these adenomas will elucidate how biologic behavior affects acromegaly treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Evidence acquisition<\/jats:title>\n                    <jats:p>We searched PubMed for relevant English-language original research and review articles on signaling pathways and molecular drivers implicated in the pathogenesis of nonfamilial somatotroph adenomas in patients with acromegaly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Evidence synthesis<\/jats:title>\n                    <jats:p>Somatotroph cells express cognate G protein\u2013coupled receptors for both hypothalamic stimulatory GH-releasing hormone (GHRH) and inhibitory somatostatin. Somatotroph GH transcription and secretion, as well as somatotroph cell lineage development, proliferation, and differentiation, are mediated by GHRH signaling through its cognate receptor (growth hormone\u2013releasing hormone receptor [GHRHR]), driving increased intracellular cyclic adenosine monophosphate (cAMP) levels. Point mutations in GNAS and other genomic and nongenomic aberrations in the tightly regulated GHRH\u2013GHRHR signaling pathway result in persistent cAMP signaling, inducing GH production and somatotroph proliferation, and potentially favoring the development of sporadic somatotroph adenomas. Enhanced cAMP signaling also increases DNA damage markers and activates DNA damage response pathways, leading to a senescent adenomatous phenotype tightly linked to GH overproduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The cAMP pathway appears to be a dominant molecular driver of somatotroph adenoma pathogenesis. Elevated cAMP drives GH hypersecretion and somatotroph proliferation and also induces DNA damage, as evidenced by increased genomic instability and a senescent signature. Collectively, these findings elucidate a molecular framework for the biological behavior of these adenomas and their responsiveness to therapies targeting cAMP-dependent pathways, including somatostatin receptor ligands.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag116","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:47:12Z","timestamp":1773330432000},"page":"S27-S37","source":"Crossref","is-referenced-by-count":0,"title":["Pathogenesis of nonfamilial somatotroph adenomas"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2912-5355","authenticated-orcid":false,"given":"Anat","family":"Ben-Shlomo","sequence":"first","affiliation":[{"name":"Department of Medicine, Pituitary Center, Cedars-Sinai Health Sciences University , Los Angeles, CA 90048 ,","place":["USA"]},{"name":"Multidisciplinary Adrenal Program, Department of Medicine, Cedars-Sinai Health Sciences University , Los Angeles, CA 90048 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2355-3447","authenticated-orcid":false,"given":"Shlomo","family":"Melmed","sequence":"additional","affiliation":[{"name":"Department of Medicine, Pituitary Center, Cedars-Sinai Health Sciences University , Los Angeles, CA 90048 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"issue":"10","key":"2026060410080085400_dgag116-B1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-tumor endocrinopathies","volume":"382","author":"Melmed","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"2026060410080085400_dgag116-B2","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","article-title":"Clinical biology of the pituitary adenoma","volume":"43","author":"Melmed","year":"2022","journal-title":"Endocr Rev"},{"issue":"3","key":"2026060410080085400_dgag116-B3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1210\/edrv-4-3-271","article-title":"Pathophysiology of acromegaly","volume":"4","author":"Melmed","year":"1983","journal-title":"Endocr Rev"},{"issue":"1","key":"2026060410080085400_dgag116-B4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","article-title":"Acromegaly","volume":"5","author":"Colao","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"2026060410080085400_dgag116-B5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S2213-8587(23)00382-0","article-title":"A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis","volume":"12","author":"Ho","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2026060410080085400_dgag116-B6","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1172\/JCI39375","article-title":"Acromegaly pathogenesis and treatment","volume":"119","author":"Melmed","year":"2009","journal-title":"J Clin Invest"},{"issue":"3","key":"2026060410080085400_dgag116-B7","doi-asserted-by":"crossref","first-page":"101895","DOI":"10.1016\/j.beem.2024.101895","article-title":"The molecular biology of sporadic acromegaly","volume":"38","author":"Marrero-Rodriguez","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"7","key":"2026060410080085400_dgag116-B8","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/jcm10071377","article-title":"Genetics of acromegaly and gigantism","volume":"10","author":"Boguslawska","year":"2021","journal-title":"J Clin Med"},{"issue":"3","key":"2026060410080085400_dgag116-B9","doi-asserted-by":"crossref","first-page":"e220291","DOI":"10.1530\/JOE-22-0291","article-title":"Pituitary tumours: molecular and genetic aspects","volume":"257","author":"De Sousa","year":"2023","journal-title":"J Endocrinol"},{"issue":"19","key":"2026060410080085400_dgag116-B10","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMra2409076","article-title":"Acromegaly","volume":"393","author":"Giustina","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"2026060410080085400_dgag116-B11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/EJE-07-0348","article-title":"The clinical, pathological, and genetic features of familial isolated pituitary adenomas","volume":"157","author":"Beckers","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2026060410080085400_dgag116-B12","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","article-title":"Acromegaly: pathogenesis, diagnosis, and management","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2026060410080085400_dgag116-B13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1210\/jc.2014-2468","article-title":"A structural and functional acromegaly classification","volume":"100","author":"Cuevas-Ramos","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026060410080085400_dgag116-B14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41574-023-00883-8","article-title":"Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification","volume":"19","author":"Ho","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"2026060410080085400_dgag116-B15","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","article-title":"A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal","volume":"31","author":"Rindi","year":"2018","journal-title":"Mod Pathol"},{"key":"2026060410080085400_dgag116-B16","first-page":"93","volume-title":"Williams Textbook of Endocrinology","author":"Lechan","year":"2024","edition":"15"},{"key":"2026060410080085400_dgag116-B17","first-page":"266","article-title":"Regulation of the pituitary somatotroph cell by GHRH and its receptor","volume":"55","author":"Mayo","year":"2000","journal-title":"Recent Prog Horm Res"},{"issue":"3","key":"2026060410080085400_dgag116-B18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11154-025-09952-x","article-title":"Growth hormone-releasing hormone receptor (GHRH-R) and its signaling","volume":"26","author":"Halmos","year":"2025","journal-title":"Rev Endocr Metab Disord"},{"issue":"2","key":"2026060410080085400_dgag116-B19","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/j.2040-4603.2016.tb00692.x","article-title":"Neuroendocrine regulation of growth hormone secretion","volume":"6","author":"Steyn","year":"2016","journal-title":"Compr Physiol"},{"issue":"11","key":"2026060410080085400_dgag116-B20","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2826.2009.01910.x","article-title":"Signalling pathway alterations in pituitary adenomas: involvement of Gsalpha, cAMP and mitogen-activated protein kinases","volume":"21","author":"Pertuit","year":"2009","journal-title":"J Neuroendocrinol"},{"issue":"1","key":"2026060410080085400_dgag116-B21","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1530\/JME-13-0172","article-title":"cAMP in the pituitary: an old messenger for multiple signals","volume":"52","author":"Peverelli","year":"2013","journal-title":"J Mol Endocrinol"},{"issue":"1-2","key":"2026060410080085400_dgag116-B22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.mce.2014.05.004","article-title":"cAMP signalling in the normal and tumorigenic pituitary gland","volume":"392","author":"Formosa","year":"2014","journal-title":"Mol Cell Endocrinol"},{"issue":"8","key":"2026060410080085400_dgag116-B23","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/35085068","article-title":"Transcriptional regulation by the phosphorylation-dependent factor CREB","volume":"2","author":"Mayr","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4-6","key":"2026060410080085400_dgag116-B24","first-page":"245","article-title":"Nuclear effects of the cAMP pathway activation in somatotrophs","volume":"47","author":"Bertherat","year":"1997","journal-title":"Horm Res"},{"issue":"6","key":"2026060410080085400_dgag116-B25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.tibs.2006.04.009","article-title":"The where's and when's of kinase anchoring","volume":"31","author":"Smith","year":"2006","journal-title":"Trends Biochem Sci"},{"key":"2026060410080085400_dgag116-B26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev.biochem.76.060305.150444","article-title":"Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling","volume":"76","author":"Conti","year":"2007","journal-title":"Annu Rev Biochem"},{"issue":"7","key":"2026060410080085400_dgag116-B27","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1111\/j.1742-4658.2009.06926.x","article-title":"Compartmentalized signalling: spatial regulation of cAMP by the action of compartmentalized phosphodiesterases","volume":"276","author":"Baillie","year":"2009","journal-title":"FEBS J"},{"key":"2026060410080085400_dgag116-B28","doi-asserted-by":"crossref","first-page":"110607","DOI":"10.1016\/j.mce.2019.110607","article-title":"Chaperones, somatotroph tumors and the cyclic AMP (cAMP)-dependent protein kinase (PKA) pathway","volume":"499","author":"Schernthaner-Reiter","year":"2020","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"2026060410080085400_dgag116-B29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11154-025-09943-y","article-title":"Update on regulation of GHRH and its actions on GH secretion in health and disease","volume":"26","author":"Montero-Hidalgo","year":"2025","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"2026060410080085400_dgag116-B30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tem.2009.12.003","article-title":"Pituitary somatostatin receptor signaling","volume":"21","author":"Ben-Shlomo","year":"2010","journal-title":"Trends Endocrinol Metab"},{"issue":"6148","key":"2026060410080085400_dgag116-B31","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/330566a0","article-title":"Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas","volume":"330","author":"Vallar","year":"1987","journal-title":"Nature"},{"issue":"6236","key":"2026060410080085400_dgag116-B32","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/340692a0","article-title":"GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours","volume":"340","author":"Landis","year":"1989","journal-title":"Nature"},{"issue":"3-4","key":"2026060410080085400_dgag116-B33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1023\/A:1009905131334","article-title":"Clinical correlates in acromegalic patients with pituitary tumors expressing GSP oncogenes","volume":"1","author":"Buchfelder","year":"1999","journal-title":"Pituitary"},{"issue":"3","key":"2026060410080085400_dgag116-B34","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11102-007-0058-2","article-title":"Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission","volume":"10","author":"Freda","year":"2007","journal-title":"Pituitary"},{"issue":"4","key":"2026060410080085400_dgag116-B35","first-page":"301","article-title":"Analysis of the Gs alpha gene in growth hormone-secreting pituitary adenomas by the polymerase chain reaction-direct sequencing method using paraffin-embedded tissues","volume":"129","author":"Hosoi","year":"1993","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"2","key":"2026060410080085400_dgag116-B36","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3803\/EnM.2020.875","article-title":"Associations of GNAS mutations with surgical outcomes in patients with growth hormone-secreting pituitary adenoma","volume":"36","author":"Jung","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"11","key":"2026060410080085400_dgag116-B37","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/cr.2016.114","article-title":"The genome-wide mutational landscape of pituitary adenomas","volume":"26","author":"Song","year":"2016","journal-title":"Cell Res"},{"issue":"1","key":"2026060410080085400_dgag116-B38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/jcm9010030","article-title":"The genetics of pituitary adenomas","volume":"9","author":"Tatsi","year":"2019","journal-title":"J Clin Med"},{"issue":"5","key":"2026060410080085400_dgag116-B39","first-page":"1604","article-title":"Pronostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas","volume":"83","author":"Barlier","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026060410080085400_dgag116-B40","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1677\/joe.0.1680221","article-title":"Prevalence of Gs alpha mutations in Korean patients with pituitary adenomas","volume":"168","author":"Kim","year":"2001","journal-title":"J Endocrinol"},{"issue":"4","key":"2026060410080085400_dgag116-B41","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-12-0864","article-title":"Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas","volume":"168","author":"Larkin","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026060410080085400_dgag116-B42","first-page":"e240266","article-title":"Somatic GNAS mutations in acromegaly: prevalence, clinical features and gender differences","volume":"14","author":"Yang","year":"2025","journal-title":"Endocr Connect"},{"issue":"6","key":"2026060410080085400_dgag116-B43","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s11102-015-0662-5","article-title":"Impact of gsp mutations in somatotroph pituitary adenomas on growth hormone response to somatostatin analogs: a meta-analysis","volume":"18","author":"Efstathiadou","year":"2015","journal-title":"Pituitary"},{"issue":"19","key":"2026060410080085400_dgag116-B44","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.3390\/cancers13194857","article-title":"Gsp mutation is not a molecular biomarker of long-term response to first-generation somatostatin receptor ligands in acromegaly","volume":"13","author":"Wildemberg","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026060410080085400_dgag116-B45","doi-asserted-by":"crossref","first-page":"1736208","DOI":"10.3389\/fendo.2026.1736208","article-title":"Clinical characteristics associated with somatic GNAS mutations in acromegaly: a systematic review and institutional experience","volume":"17","author":"Dillon","year":"2026","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2026060410080085400_dgag116-B46","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1172\/JCI11887","article-title":"Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly","volume":"107","author":"Hayward","year":"2001","journal-title":"J Clin Invest"},{"issue":"6","key":"2026060410080085400_dgag116-B47","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/ijc.22816","article-title":"Gs alpha overexpression and loss of Gs alpha imprinting in human somatotroph adenomas: association with tumor size and response to pharmacologic treatment","volume":"121","author":"Picard","year":"2007","journal-title":"Int J Cancer"},{"issue":"5","key":"2026060410080085400_dgag116-B48","first-page":"675","article-title":"Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting","volume":"22","author":"Weinstein","year":"2001","journal-title":"Endocr Rev"},{"issue":"1-2","key":"2026060410080085400_dgag116-B49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mce.2010.04.009","article-title":"GNAS imprinting and pituitary tumors","volume":"326","author":"Mantovani","year":"2010","journal-title":"Mol Cell Endocrinol"},{"key":"2026060410080085400_dgag116-B50","doi-asserted-by":"crossref","first-page":"102118","DOI":"10.1016\/j.molmet.2025.102118","article-title":"Glucose-dependent insulinotropic polypeptide (GIP)","volume":"95","author":"Muller","year":"2025","journal-title":"Mol Metab"},{"issue":"5","key":"2026060410080085400_dgag116-B51","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1507\/endocrj.50.643","article-title":"Glucose-dependent insulinotropic polypeptide induced growth hormone secretion in acromegaly","volume":"50","author":"Umahara","year":"2003","journal-title":"Endocr J"},{"issue":"7","key":"2026060410080085400_dgag116-B52","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2826.2011.02155.x","article-title":"The glucose-dependent insulinotropic polypeptide receptor is overexpressed amongst GNAS1 mutation-negative somatotropinomas and drives growth hormone (GH)-promoter activity in GH3 cells","volume":"23","author":"Occhi","year":"2011","journal-title":"J Neuroendocrinol"},{"issue":"5","key":"2026060410080085400_dgag116-B53","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1530\/EJE-16-0831","article-title":"The GIP\/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of gsp(-) somatotropinomas","volume":"176","author":"Regazzo","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026060410080085400_dgag116-B54","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1210\/clinem\/dgae583","article-title":"GIP receptor antagonism eliminates paradoxical growth hormone secretion in some patients with acromegaly","volume":"110","author":"Jensen","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026060410080085400_dgag116-B55","doi-asserted-by":"crossref","first-page":"250106","DOI":"10.1530\/ERC-25-0106","article-title":"GIPR in GH-PitNETs: molecular and functional insights","volume":"32","author":"Dalle Nogare","year":"2025","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2026060410080085400_dgag116-B56","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1210\/er.2002-0029","article-title":"Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin","volume":"25","author":"van der Lely","year":"2004","journal-title":"Endocr Rev"},{"issue":"12","key":"2026060410080085400_dgag116-B57","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1210\/en.2002-220670","article-title":"Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors","volume":"143","author":"Cunha","year":"2002","journal-title":"Endocrinology"},{"issue":"6806","key":"2026060410080085400_dgag116-B58","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/35038090","article-title":"Ghrelin induces adiposity in rodents","volume":"407","author":"Tschop","year":"2000","journal-title":"Nature"},{"issue":"2","key":"2026060410080085400_dgag116-B59","first-page":"881","article-title":"The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors","volume":"86","author":"Korbonits","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026060410080085400_dgag116-B60","doi-asserted-by":"crossref","first-page":"E2463","DOI":"10.1210\/jc.2014-2753","article-title":"Ghrelin receptor (GHS-R1a) and its constitutive activity in somatotroph adenomas: a new co-targeting therapy using GHS-R1a inverse agonists and somatostatin analogs","volume":"99","author":"Mear","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026060410080085400_dgag116-B61","doi-asserted-by":"crossref","first-page":"100042","DOI":"10.1016\/j.pharmr.2025.100042","article-title":"Cyclic nucleotide phosphodiesterases as drug targets","volume":"77","author":"Kelly","year":"2025","journal-title":"Pharmacol Rev"},{"key":"2026060410080085400_dgag116-B62","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3389\/fendo.2019.00141","article-title":"Phosphodiesterases and cAMP pathway in pituitary diseases","volume":"10","author":"Bizzi","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2026060410080085400_dgag116-B63","first-page":"1624","article-title":"Constitutively active Gs alpha is associated with an increased phosphodiesterase activity in human growth hormone-secreting adenomas","volume":"83","author":"Lania","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2026060410080085400_dgag116-B64","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.mce.2018.04.014","article-title":"Reduced protein expression of the phosphodiesterases PDE4A4 and PDE4A8 in AIP mutation positive somatotroph adenomas","volume":"476","author":"Bizzi","year":"2018","journal-title":"Mol Cell Endocrinol"},{"issue":"8","key":"2026060410080085400_dgag116-B65","first-page":"3795","article-title":"Relevant cAMP-specific phosphodiesterase isoforms in human pituitary: effect of Gs(alpha) mutations","volume":"86","author":"Persani","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026060410080085400_dgag116-B66","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1210\/jc.2006-1731","article-title":"Aryl hydrocarbon receptor interacting protein variants in sporadic pituitary adenomas","volume":"91","author":"Yu","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026060410080085400_dgag116-B67","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1210\/jc.2007-2611","article-title":"The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas","volume":"93","author":"Leontiou","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026060410080085400_dgag116-B68","doi-asserted-by":"crossref","first-page":"E663","DOI":"10.1210\/jc.2011-2291","article-title":"Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients","volume":"97","author":"Cazabat","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026060410080085400_dgag116-B69","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1530\/EJE-11-0304","article-title":"High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas","volume":"165","author":"Tichomirowa","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"35","key":"2026060410080085400_dgag116-B70","doi-asserted-by":"crossref","first-page":"33351","DOI":"10.1074\/jbc.M303269200","article-title":"Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2","volume":"278","author":"Bolger","year":"2003","journal-title":"J Biol Chem"},{"issue":"18","key":"2026060410080085400_dgag116-B71","doi-asserted-by":"crossref","first-page":"13656","DOI":"10.1074\/jbc.M610942200","article-title":"Phosphodiesterase 2A forms a complex with the co-chaperone XAP2 and regulates nuclear translocation of the aryl hydrocarbon receptor","volume":"282","author":"de Oliveira","year":"2007","journal-title":"J Biol Chem"},{"issue":"2","key":"2026060410080085400_dgag116-B72","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1210\/jc.2007-1451","article-title":"Assessment of the magnitude of growth hormone hypersecretion in active acromegaly: reliability of different sampling models","volume":"93","author":"Bajuk Studen","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026060410080085400_dgag116-B73","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2265.1992.tb02304.x","article-title":"The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex","volume":"37","author":"van der Lely","year":"1992","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"2026060410080085400_dgag116-B74","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1210\/jc.2015-3129","article-title":"Whole-genome sequencing of growth hormone (GH)-secreting pituitary adenomas","volume":"100","author":"Valimaki","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026060410080085400_dgag116-B75","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1158\/1078-0432.CCR-16-0790","article-title":"Landscape of genomic alterations in pituitary adenomas","volume":"23","author":"Bi","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2026060410080085400_dgag116-B76","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.1172\/JCI138540","article-title":"DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas","volume":"130","author":"Ben-Shlomo","year":"2020","journal-title":"J Clin Invest"},{"issue":"1","key":"2026060410080085400_dgag116-B77","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/s42003-022-04272-1","article-title":"Proteogenomic landscape and clinical characterization of GH-producing pituitary adenomas\/somatotroph pituitary neuroendocrine tumors","volume":"5","author":"Yamato","year":"2022","journal-title":"Commun Biol"},{"issue":"6","key":"2026060410080085400_dgag116-B78","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1210\/jc.2011-2930","article-title":"Clinical characteristics and outcome of acromegaly induced by ectopic secretion of growth hormone-releasing hormone (GHRH): a French nationwide series of 21 cases","volume":"97","author":"Garby","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026060410080085400_dgag116-B79","doi-asserted-by":"crossref","first-page":"867965","DOI":"10.3389\/fendo.2022.867965","article-title":"Acromegaly caused by ectopic growth hormone releasing hormone secretion: a review","volume":"13","author":"Zendran","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2026060410080085400_dgag116-B80","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ando.2012.09.004","article-title":"Acromegaly induced by ectopic secretion of GHRH: a review 30 years after GHRH discovery","volume":"73","author":"Borson-Chazot","year":"2012","journal-title":"Ann Endocrinol (Paris)"},{"issue":"3","key":"2026060410080085400_dgag116-B81","doi-asserted-by":"crossref","first-page":"101877","DOI":"10.1016\/j.beem.2024.101877","article-title":"The clinical and biochemical spectrum of ectopic acromegaly","volume":"38","author":"Fainstein-Day","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"9","key":"2026060410080085400_dgag116-B82","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1210\/endo.142.9.8382","article-title":"The effect of GHRH on somatotrope hyperplasia and tumor formation in the presence and absence of GH signaling","volume":"142","author":"Kineman","year":"2001","journal-title":"Endocrinology"},{"issue":"4","key":"2026060410080085400_dgag116-B83","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1124\/pr.117.015388","article-title":"International union of basic and clinical pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature","volume":"70","author":"Gunther","year":"2018","journal-title":"Pharmacol Rev"},{"issue":"8","key":"2026060410080085400_dgag116-B84","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1210\/jcem.86.8.7787","article-title":"Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment","volume":"86","author":"Ballare","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026060410080085400_dgag116-B85","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1530\/EJE-11-0416","article-title":"Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly","volume":"165","author":"Ciganoka","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2026060410080085400_dgag116-B86","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1210\/jc.2009-2247","article-title":"A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs","volume":"95","author":"Duran-Prado","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026060410080085400_dgag116-B87","doi-asserted-by":"crossref","first-page":"R223","DOI":"10.1530\/JME-14-0011","article-title":"Somatostatin receptor ligands and resistance to treatment in pituitary adenomas","volume":"52","author":"Cuevas-Ramos","year":"2014","journal-title":"J Mol Endocrinol"},{"issue":"1","key":"2026060410080085400_dgag116-B88","doi-asserted-by":"crossref","first-page":"e13313","DOI":"10.1111\/bpa.13313","article-title":"Somatostatin receptors in pituitary somatotroph adenomas as predictors of response to somatostatin receptor ligands: a pathologist's perspective","volume":"35","author":"Botelho","year":"2025","journal-title":"Brain Pathol"},{"issue":"6","key":"2026060410080085400_dgag116-B89","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1210\/endrev\/bnaa006","article-title":"Novel insights into pituitary tumorigenesis: genetic and epigenetic mechanisms","volume":"41","author":"Srirangam Nadhamuni","year":"2020","journal-title":"Endocr Rev"},{"issue":"7","key":"2026060410080085400_dgag116-B90","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1210\/en.2016-1967","article-title":"Clinical identification of oncogenic drivers and copy-number alterations in pituitary tumors","volume":"158","author":"Bi","year":"2017","journal-title":"Endocrinology"},{"issue":"5","key":"2026060410080085400_dgag116-B91","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/jc.2017-02287","article-title":"Genomic alterations and complex subclonal architecture in sporadic GH-secreting pituitary adenomas","volume":"103","author":"Hage","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060410080085400_dgag116-B92","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccell.2019.11.002","article-title":"Pangenomic classification of pituitary neuroendocrine tumors","volume":"37","author":"Neou","year":"2020","journal-title":"Cancer Cell"},{"issue":"1","key":"2026060410080085400_dgag116-B93","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s40478-020-01067-5","article-title":"Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis","volume":"8","author":"Lasolle","year":"2020","journal-title":"Acta Neuropathol Commun"},{"issue":"12","key":"2026060410080085400_dgag116-B94","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41422-022-00736-5","article-title":"Integrated proteogenomic characterization across major histological types of pituitary neuroendocrine tumors","volume":"32","author":"Zhang","year":"2022","journal-title":"Cell Res"},{"issue":"45","key":"2026060410080085400_dgag116-B95","doi-asserted-by":"crossref","first-page":"17498","DOI":"10.1073\/pnas.0804810105","article-title":"P21(Cip1) restrains pituitary tumor growth","volume":"105","author":"Chesnokova","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"35","key":"2026060410080085400_dgag116-B96","doi-asserted-by":"crossref","first-page":"E3331","DOI":"10.1073\/pnas.1310589110","article-title":"Growth hormone is a cellular senescence target in pituitary and nonpituitary cells","volume":"110","author":"Chesnokova","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2026060410080085400_dgag116-B97","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1210\/mend.11.4.9911","article-title":"Isolation and characterization of a pituitary tumor-transforming gene (PTTG)","volume":"11","author":"Pei","year":"1997","journal-title":"Mol Endocrinol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag116\/67342106\/dgag116.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/Supplement_1\/S27\/67342106\/dgag116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/Supplement_1\/S27\/67342106\/dgag116.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:08:23Z","timestamp":1780582103000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/Supplement_1\/S27\/8519559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":97,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2026,3,13]]},"published-print":{"date-parts":[[2026,6,4]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag116","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,3,13]]}}}